Cellbox Solutions, a developer of innovative logistics solutions for the global BioMed industry, has secured $4.1 million in new investment capital. This funding round marks a significant milestone for the company, which specializes in ensuring the safe transport of living cells and biological samples.
The company's flagship product is a portable incubator featuring active CO₂ and temperature control. This device maintains optimal laboratory conditions, such as 37°C and 5% CO₂, crucial for the viability of fragile biological material during transit. The concept for Cellbox™ originated at Fraunhofer EMB in Lübeck, where researchers identified a critical need for such a solution. A dedicated team of engineers and biologists subsequently developed the robust Cellbox™ incubator.
The newly raised capital will be instrumental in accelerating Cellbox Solutions' strategic growth initiatives. The company plans to utilize the funds to scale its operations, expand its market presence, and continue the development of its specialized logistics technology. This investment underscores confidence in Cellbox Solutions' ability to address complex challenges within the BioMed supply chain.
Cellbox Solutions currently collaborates with over 150 customers, addressing diverse cell transport requirements and continuously refining its product offerings. The development and assembly of Cellbox™ incubators have been supported by Fraunhofer EMB and an European EIC grant. Furthermore, the company recently established a collaboration with Biospherix, a US firm focused on closed-system cell culture technologies, enhancing its capabilities and reach.
Looking ahead, Cellbox Solutions aims to further solidify its position as a key provider of advanced cell transport solutions. The company is committed to ongoing innovation, ensuring that critical biological materials can be transported globally while maintaining their integrity and viability, thereby supporting advancements in research and therapeutic applications.
